These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 25306885)
1. Assessing the utility of testing aluminum levels in dialysis patients. Sharma AK; Toussaint ND; Pickering J; Beeston T; Smith ER; Holt SG Hemodial Int; 2015 Apr; 19(2):256-62. PubMed ID: 25306885 [TBL] [Abstract][Full Text] [Related]
2. What is the value of plasma/serum aluminum in patients with chronic renal failure? Winney RJ; Cowie JF; Robson JS Clin Nephrol; 1985; 24 Suppl 1():S2-8. PubMed ID: 3842104 [TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
4. Plasma aluminium: a redundant test for patients on dialysis? Gault PM; Allen KR; Newton KE Ann Clin Biochem; 2005 Jan; 42(Pt 1):51-4. PubMed ID: 15802033 [TBL] [Abstract][Full Text] [Related]
5. Low serum aluminum values in dialysis patients with increased bone aluminum levels. van Landeghem GF; D'Haese PC; Lamberts LV; Djukanovic L; Pejanovic S; Goodman WG; De Broe ME Clin Nephrol; 1998 Aug; 50(2):69-76. PubMed ID: 9725776 [TBL] [Abstract][Full Text] [Related]
7. [Hyperaluminemia in chronic hemodialysis patients. Evaluation of the respective roles of dialysate aluminum and oral aluminum hydroxide]. Tahiri Y; Moriniere P; Jaudon MC; Dkhissi H; Rosa A; Fournier A Nephrologie; 1983; 4(3):129-33. PubMed ID: 6633778 [TBL] [Abstract][Full Text] [Related]
8. Do oral aluminium phosphate binders cause accumulation of aluminium to toxic levels? Pepper R; Campbell N; Yaqoob MM; Roberts NB; Fan SL BMC Nephrol; 2011 Oct; 12():55. PubMed ID: 21992770 [TBL] [Abstract][Full Text] [Related]
9. [Prevalence of histological types of bone disease in a hemodialysis center limiting the oral intake of aluminum hydroxide]. Belbrik S; Marie A; Boudailliez B; Morinière P; Sébert JL; Solal MC; Westeel PF; Roche D; Fournier A Nephrologie; 1990; 11(2):83-90. PubMed ID: 2392208 [TBL] [Abstract][Full Text] [Related]
12. [Indirect evaluation of the effect of 1 alpha-hydroxyvitamin D3 on intestinal absorption of aluminum]. Demontis R; Reissi D; Noël C; Morinière P; Renaud H; Leflon P; Westeel PF; Brasseur J; Coevoet B; Fournier A Nephrologie; 1988; 9(3):135-8. PubMed ID: 3194044 [TBL] [Abstract][Full Text] [Related]
13. The effect of oral aluminium therapy on plasma aluminium levels in patients with chronic renal failure in an area with low water aluminium. Fleming LW; Stewart Wk; Fell GS; Halls DJ Clin Nephrol; 1982 May; 17(5):222-7. PubMed ID: 7094439 [TBL] [Abstract][Full Text] [Related]
14. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Kausz AT; Antonsen JE; Hercz G; Pei Y; Weiss NS; Emerson S; Sherrard DJ Am J Kidney Dis; 1999 Oct; 34(4):688-93. PubMed ID: 10516350 [TBL] [Abstract][Full Text] [Related]
15. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. Salusky IB; Foley J; Nelson P; Goodman WG N Engl J Med; 1991 Feb; 324(8):527-31. PubMed ID: 1992306 [TBL] [Abstract][Full Text] [Related]
16. [Elimination of aluminum via continuous ambulatory peritoneal dialysis]. Passlick J; Wilhelm M; Busch T; Grabensee B; Ohnesorge FK Dtsch Med Wochenschr; 1989 Jan; 114(1):9-13. PubMed ID: 2910699 [TBL] [Abstract][Full Text] [Related]
17. [Aluminum and magnesium burden of dialysis patients using antacids. A comparative study]. Eichhorn M Fortschr Med; 1989 Aug; 107(23):502-6. PubMed ID: 2670719 [TBL] [Abstract][Full Text] [Related]